# Royalty Pharma plc (RPRX) FY2024 Q3 P&L / Income Statement

- Company: Royalty Pharma plc (RPRX)
- Period: 2024-07-01 to 2024-09-30
- Filing: Q3 FY2024 10-Q, filed 2024-11-06, accession number 0001802768-24-000058
- Page: https://plicit.ai/financials/rprx/fy2024-q3-income-statement
- Chart image: https://plicit.ai/charts/rprx-fy2024-q3-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2024-07-01 through 2024-09-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total income and other revenues**: 564,690,000 US dollars
- **Total operating (income)/expense, net**: negative 170,384,000 US dollars
- **Operating income**: 735,074,000 US dollars
- **Total other (income)/expense, net**: 71,284,000 US dollars
- **Consolidated net income before tax**: 806,358,000 US dollars
- **Income tax expense**: 0 US dollars
- **Consolidated net income**: 806,358,000 US dollars
- **Income from financial royalty assets**: 533,166,000 US dollars
- **Other royalty income and revenues**: 31,524,000 US dollars
- **Research and development funding expense**: 500,000 US dollars
- **Provision for changes in expected cash flows from financial royalty assets**: negative 227,604,000 US dollars
- **General and administrative expenses**: 56,720,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to Royalty Pharma plc: $543.99 M; to noncontrolling interests: $262.37 M.